Daiichi Sankyo and AstraZeneca’s Enhertu has received approval from China’s NMPA for adult patients with locally advanced or ...

As more drugs go subcutaneous, CEO of Phillips Medisize, Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.

This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the upcoming patent cliff.

Deaths linked to cardiovascular diseases are down, though stroke and heart disease are still in the top five leading causes ...

J&J has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising by 49.1% to $5.11bn.

Opna Bio has received the US FDA orphan drug designation for OPN-2853, a BET small molecule inhibitor, to treat myelofibrosis.

Speaking at the World Economic Forum in Davos, Donald Trump said tariffs helped fix the long-time drug pricing scam in the US ...

Staying ahead of pharma supply challenges rests on anticipatory pillars and does not require reinventing the wheel, says ...

Logistics companies provide an essential service for clinical trials, but providers must be compliant with regulations. Learn ...

Pfizer has signed a deal worth up to $530m with US-based vaccine technology company Novavax. This agreement will see Pfizer ...

Bristol Myers Squibb (BMS) has entered into an agreement with Microsoft to advance AI-driven early lung cancer detection.